Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Nature Reviews. Cancer

• Publication date

  2013-03-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrc3498PMID 23535846
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The strategy of the genes : a discussion of some aspects of theoretical biology

  2014cited by this paper
• Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties.

  2013cited by this paper
• Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer

  2013cited by this paper
• Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

  2013cited by this paper
• EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

  2012cited by this paper
• A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.

  2012cited by this paper
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.

  2012cited by this paper
• Pushing the limits of targeted therapy in chronic myeloid leukaemia

  2012cited by this paper
• A Race between Tumor Immunoescape and Genome Maintenance Selects for Optimum Levels of (epi)genetic Instability

  2012cited by this paper
• Evolutionary dynamics of carcinogenesis and why targeted therapy does not work

  2012cited by this paper
• Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

  2012cited by this paper
• Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

  2012cited by this paper
• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012cited by this paper
• Systematic classification of melanoma cells by phenotype‐specific gene expression mapping

  2012cited by this paper
• Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer

  2012cited by this paper
• The tumor microenvironment is a dominant force in multidrug resistance.

  2012cited by this paper
• Melanoma: from mutations to medicine.

  2012cited by this paper
• Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.

  2012cited by this paper
• MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling.

  2012cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

  2012cited by this paper
• Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth

  2012cited by this paper
• Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes.

  2012cited by this paper
• Transcriptional and epigenetic control of T helper cell specification: molecular mechanisms underlying commitment and plasticity.

  2012cited by this paper
• PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.

  2012cited by this paper
• Multi-time scales in adaptive dynamics: microscopic interpretation of a trait substitution tree model

  2012cited by this paper
• Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance.

  2012cited by this paper
• A CXCL1 paracrine network links cancer chemoresistance and metastasis.

  2012cited by this paper
• A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread.

  2012cited by this paper
• A Multi-Cancer Mesenchymal Transition Gene Expression Signature Is Associated with Prolonged Time to Recurrence in Glioblastoma

  2012cited by this paper
• Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies.

  2012cited by this paper
• Adoptive immunotherapy for cancer: harnessing the T cell response

  2012cited by this paper
• Macrophage plasticity and polarization: in vivo veritas.

  2012cited by this paper
• Intra-tumour heterogeneity: a looking glass for cancer?

  2012cited by this paper
• Chromosomal instability and cancer: a complex relationship with therapeutic potential.

  2012cited by this paper
• Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia.

  2012cited by this paper
• Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype

  2012cited by this paper
• Imaging Molecular Pathways: Reporter Genes

  2012cited by this paper
• Cancer stem cells: impact, heterogeneity, and uncertainty.

  2012cited by this paper
• Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

  2012cited by this paper
• Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

  2012cited by this paper
• Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Clonal evolution in cancer

  2012cited by this paper
• Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

  2012cited by this paper
• Melanoma revives an embryonic migration program to promote plasticity and invasion

  2012cited by this paper
• An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

  2012cited by this paper
• Accessories to the crime: functions of cells recruited to the tumor microenvironment.

  2012cited by this paper
• Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?

  2012cited by this paper
• A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer.

  2011cited by this paper
• Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer.

  2011cited by this paper
• Abstract 3341: TGFβ/ TNFα-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype

  2011cited by this paper
• Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

  2011cited by this paper
• Resistance, epigenetics and the cancer ecosystem

  2011cited by this paper
• T cell exhaustion

  2011cited by this paper
• Chemotherapeutic resistance: surviving stressful situations.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.

  2011cited by this paper
• Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth.

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Exact solution of a two-type branching process: models of tumor progression

  2011cited by this paper
• Genetic variegation of clonal architecture and propagating cells in leukaemia

  2011cited by this paper
• Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells

  2011cited by this paper
• Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.

  2011cited by this paper
• Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.

  2011cited by this paper
• Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model

  2011cited by this paper
• Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

  2011cited by this paper
• Metabolic tumor imaging using magnetic resonance spectroscopy.

  2011cited by this paper
• The cancer stem cell: premises, promises and challenges

  2011cited by this paper
• Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort

  2011cited by this paper
• Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny

  2011cited by this paper
• The parallel lives of angiogenesis and immunosuppression: cancer and other tales

  2011cited by this paper
• Long-term single-cell imaging of mammalian stem cells

  2011cited by this paper
• The cadherin switch in melanoma instigated by HGF is mediated through epithelial–mesenchymal transition regulators

  2011cited by this paper
• TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype.

  2011cited by this paper
• Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells

  2011cited by this paper
• GLI2 and M‐MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells

  2011cited by this paper
• BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis

  2011cited by this paper
• Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells

  2011cited by this paper
• Cancer immunotherapy comes of age

  2011cited by this paper
• Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011cited by this paper
• Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells.

  2011cited by this paper
• Mutant BRAF melanomas--dependence and resistance.

  2011cited by this paper
• Mesenchymal Transition and Dissemination of Cancer Cells Is Driven by Myeloid-Derived Suppressor Cells Infiltrating the Primary Tumor

  2011cited by this paper
• F1000 highlights

  2010cited by this paper
• Interferon-γ links UV to melanocyte activation and promotes melanomagenesis

  2010cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• DNA damage-mediated induction of a chemoresistant niche.

  2010cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010cited by this paper
• A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.

  2010cited by this paper
• TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Autochthonous primary and metastatic melanomas in Hgf‐Cdk4R24C mice evade T‐cell‐mediated immune surveillance

  2010cited by this paper
• Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice.

  2010cited by this paper

• Periodontitis-Induced Immune Reprogramming: Implications for Cancer Immunotherapy Response.

  2026cites this paper
• The landscape of cell lineage tracing

  2025cites this paper
• Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf

  2025cites this paper
• A guide to transcriptomic deconvolution in cancer

  2025cites this paper
• A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK‐β

  2025cites this paper
• Embryonic stem cell factors DPPA2/4 facilitate a unique chromatin state in non-small cell lung cancer

  2025cites this paper
• Epigenetic mechanisms in melanoma development and progression.

  2025cites this paper
• Matrix Metalloproteinase-9 is associated with tumor microenvironment remodeling of bladder cancer

  2025cites this paper
• Tumour Single‐Cell Bioinformatics: From Immune Profiling to Molecular Dynamics

  2025cites this paper
• TC2N maintains stem cell-like characteristics to accelerate lung carcinogenesis by blockade of dual specificity protein phosphatase 3

  2025cites this paper
• [High expression of DTX2 promotes proliferation, invasion and epithelial-mesenchymal transition of oxaliplatin-resistant colorectal cancer cells].

  2025cites this paper
• Cancer Associated Fibroblasts-derived Lactate Induces Oxaliplatin Treatment Resistance by Promoting Cancer Stemness via ANTXR1 Lactylation in Colorectal Cancer.

  2025cites this paper
• Bimetal‐Biligand Frameworks for Spatiotemporal Nitric Oxide‐Enhanced Sono‐Immunotherapy

  2024cites this paper
• Molecular Targets for Breast Cancer Therapy

  2024cites this paper
• NIR-715 photodynamic therapy induces immunogenic cancer cell death by enhancing the endoplasmic reticulum stress response

  2024cites this paper
• Mapping intratumoral myeloid-T cell interactomes at single-cell resolution reveals targets for overcoming checkpoint inhibitor resistance

  2024cites this paper
• Development of a Macrophage-Related Risk Model for Metastatic Melanoma

  2023cites this paper
• Crossroad between the Heat Shock Protein and Inflammation Pathway in Acquiring Drug Resistance: A Possible Target for Future Cancer Therapeutics

  2023cites this paper
• PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer

  2023cites this paper
• Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling

  2023cites this paper
• Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories

  2023cites this paper
• The CD73 is induced by TGF-β1 triggered by nutrient deprivation and highly expressed in dedifferentiated human melanoma.

  2023cites this paper
• Circulating H3K27 Methylated Nucleosome plasma concentration: a synergic information with ctDNA Molecular Profiling

  2023cites this paper
• Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

  2023cites this paper
• Indolent cancer and pattern of progression: Two missing parameters in trial design for hepatology

  2023cites this paper
• BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers

  2023cites this paper
• Current and Emerging Strategies to Treat Urothelial Carcinoma

  2023cites this paper
• m6A epitranscriptome analysis reveals differentially methylated transcripts that drive early chemoresistance in bladder cancer

  2023cites this paper
• Programmed Nanoreactors Boost Immune Response through ROS Cascade Amplification along with RNS Storm

  2023cites this paper
• A comprehensive survey into the role of exosomes in pancreatic cancer; from the origin of cancer to the progress and possibility of diagnosis and treatment.

  2023cites this paper
• Immunology and immunotherapy of cholangiocarcinoma

  2023cites this paper
• Dedifferentiated Endometrial Carcinoma: A Rare Aggressive Neoplasm-Clinical, Morphological and Immunohistochemical Features

  2023cites this paper
• Implications of single-cell immune landscape of tumor microenvironment for the colorectal cancer diagnostics and therapy

  2023cites this paper
• Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies

  2023cites this paper
• Current trends in gas-synergized phototherapy for improved antitumor theranostics.

  2023cites this paper
• Scales of Cancer Evolution: Selfish Genome or Cooperating Cells?

  2022cites this paper
• Case report: Mafb promoter activity may define the alveolar macrophage dichotomy

  2022cites this paper
• Connecting Metabolic Rewiring With Phenotype Switching in Melanoma

  2022cites this paper
• Microfluidic-Based Technologies for CTC Isolation: A Review of 10 Years of Intense Efforts towards Liquid Biopsy

  2022cites this paper
• Aspirin activates resolution pathways to reprogram T cell and macrophage responses in colitis-associated colorectal cancer

  2022cites this paper
• Hepatocellular Carcinoma: The Role of MicroRNAs

  2022cites this paper
• PLAG co-treatment increases the anticancer effect of Adriamycin and cyclophosphamide in a triple-negative breast cancer xenograft mouse model.

  2022cites this paper
• Implication of COPB2 Expression on Cutaneous Squamous Cell Carcinoma Pathogenesis

  2022cites this paper
• Tumour Stem Cells in Breast Cancer

  2022cites this paper
• Single-cell level temporal profiling of tumour-reactive T cells under immune checkpoint blockade

  2022cites this paper
• Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy

  2022cites this paper
• The chemical Langevin equation for biochemical systems in dynamic environments

  2022cites this paper
• Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents

  2022cites this paper
• Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer

  2022cites this paper
• Interplay Between Chemotherapy-Activated Cancer Associated Fibroblasts and Cancer Initiating Cells Expressing CD44v6 Promotes Colon Cancer Resistance

  2022cites this paper
• Light-Triggered Polymeric Prodrug and Nano-assembly for Chemo-Photodynamic Therapy and Potentiate Immune Checkpoint Blockade Immunotherapy for Hepatocellular Carcinoma

  2022cites this paper
• Bioplatforms in liquid biopsy: advances in the techniques for isolation, characterization and clinical applications

  2022cites this paper
• A hybrid modeling environment to describe aggregates of cells heterogeneous for genotype and behavior with possible phenotypic transitions

  2022cites this paper
• An efficient rectangular optimization method for sparse orthogonal collimator based small animal irradiation

  2022cites this paper
• Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma

  2022cites this paper
• Complex RNA world in small extracellular vesicles for liquid biopsy in cancer management

  2022cites this paper
• CD73, Tumor Plasticity and Immune Evasion in Solid Cancers

  2021cites this paper
• Dormant Tumor Cell Vaccination: A Mathematical Model of Immunological Dormancy in Triple-Negative Breast Cancer

  2021cites this paper
• Tumor-intrinsic determinants of immunogenic cell death modalities

  2021cites this paper
• The dual role of Natural Killer cells during tumor progression and angiogenesis: Implications for tumor microenvironment-targeted immunotherapies

  2021cites this paper
• The tumor immune microenvironments of HPV+ and HPV- head and neck cancers.

  2021cites this paper
• Biosynthetic exosome nanoparticles isolation, characterization, and their diagnostic and therapeutic applications

  2021cites this paper
• Preclinical models in oncological pharmacology: limits and advantages

  2021cites this paper
• Phenotypic plasticity: The emergence of cancer stem cells, collective cell migration, and the impact on immune surveillance

  2021cites this paper
• Multifunctional Nanocarriers-Mediated Synergistic Combination of Immune Checkpoint Inhibitor Cancer Immunotherapy and Interventional Oncology Therapy.

  2021cites this paper
• Cancer immunoediting by melanocyte differentiation antigen-specific T cells determines response to immune checkpoint inhibition

  2021cites this paper
• In-vitro tumor microenvironment models containing physical and biological barriers for modelling multidrug resistance mechanisms and multidrug delivery strategies.

  2021cites this paper
• The myeloid cell type I IFN system promotes antitumor immunity over pro‐tumoral inflammation in cancer T‐cell therapy

  2021cites this paper
• Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy

  2021cites this paper
• Single‐Domain Multiferroic Array‐Addressable Terfenol‐D (SMArT) Micromagnets for Programmable Single‐Cell Capture and Release

  2021cites this paper
• Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy

  2021cites this paper
• Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma

  2021cites this paper
• EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer

  2021cites this paper
• Tumor extracellular vesicles loaded with exogenous Let-7i and miR-142 can modulate both immune response and tumor microenvironment to initiate a powerful anti-tumor response.

  2020cites this paper
• A Tissue Engineering Approach to Metastatic Colon Cancer

  2020influential citation
• Inter-Relationship Between the Inflammation and Heat Shock Protein in Cancer Development: A Possible Target for Diagnosis and Cancer Immunotherapy

  2020cites this paper
• The lipogenic regulator SREBF2 induces Transferrin in circulating melanoma cells and suppresses ferroptosis.

  2020cites this paper
• The mitophagy effector FUNDC1 controls mitochondrial reprogramming and cellular plasticity in cancer cells

  2020cites this paper
• Genomic profiling of a dedifferentiated mucosal melanoma following exposure to immunotherapy

  2020cites this paper
• Fluorescent glycan nanoparticle-based FACS assays for the identification of genuine drug-resistant cancer cells with differentiation potential

  2020cites this paper
• Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel

  2020cites this paper
• How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy

  2020cites this paper
• Cell-mediated immune resistance in cancer

  2020cites this paper
• DIY: Visualizing the immune landscape of tumors using transcriptome and methylome data.

  2020cites this paper
• An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia

  2020cites this paper
• Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy.

  2020cites this paper
• Review on biofabrication and applications of heterogeneous tumor models

  2019cites this paper
• Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death

  2019cites this paper
• Tumor Niche Disruption and Metastasis: The Role of Epithelial-Mesenchymal Transition (EMT)

  2019cites this paper
• Cellular and molecular biology of cancer stem cells in melanoma: possible therapeutic implications.

  2019cites this paper
• Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment.

  2019cites this paper
• Molecular and Cell Biology of Cancer

  2019cites this paper
• Intratumor Heterogeneity

  2019cites this paper
• Acquired resistance during adoptive cell therapy by transcriptional silencing of immunogenic antigens

  2019cites this paper
• Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy

  2019cites this paper
• Intercellular Crosstalk via Extracellular Vesicles in Tumor Milieu as Emerging Therapies for Cancer Progression.

  2019cites this paper
• IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.

  2019cites this paper
• The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture

  2019cites this paper
• Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways

  2019cites this paper
• Combinational delivery therapies of nucleic acids for cancer treatment

  2019cites this paper